Outperform Maintained on ASND Ascendis Pharma A/S by Evercore Mar 02, 2026

Evercore ISI maintained an Outperform rating on Ascendis Pharma A/S (ASND) on March 02, 2026 and raised its price target to $324, setting the tone for the day’s coverage. The ASND analyst rating mix also included Wolfe Research maintaining Outperform with a new $260 target and Cantor Fitzgerald reiterating Overweight. These three March 02, 2026 actions together pushed short-term investor interest higher and correlated with intraday moves of roughly 2.8%–3.9% in ASND price activity.